Biovie INC 8-K filings

BioVie Inc. announced positive topline results from its Phase 2 SUNRISE-PD trial evaluating bezisterim for early-stage Parkinson's disease, showing significant improvements in motor and non-motor symptoms and a favorable safety profile.

BioVie Inc. stockholders approved an amendment to its 2019 Omnibus Equity Incentive Plan, increasing authorized shares to 3.1 million to enhance talent retention and alignment.

BioVie Inc. announced the results of its 2025 annual meeting, including the election of directors and the approval of an amended equity incentive plan.

BioVie Inc. successfully closed its public offering, raising approximately $12 million in gross proceeds to fund working capital and general corporate purposes.

BioVie Inc. announced the expansion of its Board of Directors from four to six members, appointing Dr. Amy S. Chappell and Kameel D. Farag, effective immediately.

BioVie Inc. has announced that its Board of Directors has approved a one-for-ten reverse stock split of its Class A common stock, effective July 7, 2025, following stockholder approval.

BioVie Inc. stockholders have granted the company's Board of Directors the authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10 within the next year.

Dr. Robert Hariri resigned from BioVie Inc.'s Board of Directors, effective March 28, 2025, with no reported disagreements with the company.

BioVie Inc. held its 2024 Annual Meeting of Stockholders on November 7, 2024, where directors were elected, auditors were ratified, executive compensation was approved, and an equity incentive plan was amended.

BioVie Inc. successfully closed a registered direct offering, raising approximately $3.2 million before expenses, to support working capital and general corporate purposes.

BioVie Inc. has announced a registered direct offering of 1,146,000 shares of its common stock at a price of $2.83 per share, expected to generate approximately $3.2 million in gross proceeds.

BioVie Inc. has successfully closed a registered direct offering and concurrent private placement, raising approximately $6 million before expenses.

BioVie Inc. has priced a registered direct offering of common stock and concurrent private placement of warrants, expected to generate gross proceeds of approximately $6 million.

BioVie Inc. successfully closed a registered direct offering and concurrent private placement, raising approximately $6.7 million before expenses.

BioVie Inc. has priced a registered direct offering of common stock and warrants, aiming to raise approximately $6.66 million for working capital and general corporate purposes.

BioVie Inc. successfully closed a public offering, raising approximately $3 million, and adjusted the exercise price of a warrant held by Acuitas Group Holdings.

BioVie Inc. filed an amendment to its previous 8-K report to include an updated legal opinion regarding the issuance of shares and warrants.

BioVie Inc. has announced a public offering to sell shares of its common stock and warrants, aiming to raise approximately $3 million.

BioVie Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.

BioVie Inc. filed an amendment to its previous 8-K report to correct a defect in the filing related to a one-for-ten reverse stock split.

BioVie Inc. will implement a 1-for-10 reverse stock split of its common stock, effective August 6, 2024, following shareholder approval at a special meeting.

Steve Gorlin has resigned from the Board of Directors of BioVie Inc., effective immediately, with no disputes cited as the reason.

BioVie Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing the company at risk of delisting.

BioVie Inc. has announced updates to its drug pipeline, prioritizing a Phase 2b trial for Parkinson's disease while also advancing its Alzheimer's and liver disease programs.

BioVie Inc. has successfully closed a public offering, raising approximately $21 million, and adjusted the exercise price of a warrant held by Acuitas Group Holdings.

BioVie Inc. filed an amendment to its previous 8-K report to include legal opinions related to its recent offering of shares and warrants, aiming to raise up to $21 million.

BioVie Inc. has announced a public offering to sell up to 21 million shares of common stock and warrants, aiming to raise approximately $21 million for working capital and general corporate purposes.

BioVie Inc. announced presentations at the International Conference on Alzheimer's and Parkinson's Diseases 2024, highlighting positive results for NE3107 in both Parkinson's and Alzheimer's disease trials.

BioVie Inc. is facing a shareholder class action lawsuit alleging misrepresentations and omissions related to its business, operations, and the NE3107 study.

BioVie Inc. has filed a prospectus supplement related to its existing Controlled Equity Offering, aiming to raise up to $25 million through the sale of Class A common stock.